Vistagen announces completion of palisade-1 phase 3 clinical study of ph94b for the acute treatment of social anxiety disorder

South san francisco, calif.--(business wire)---- $vtgn #vistagen--vistagen announces completion of palisade-1 phase 3 clinical trial of ph94b for the acute treatment of anxiety in adults with social anxiety disorder
VTGN Ratings Summary
VTGN Quant Ranking